| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | 0.049 | 0.2 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | 0.049 | 0.2 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | -0.052 | 0.2 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.05 | 0.2 |
| mRNA | BI-2536 | FIMM | pan-cancer | AAC | 0.15 | 0.2 |
| mRNA | AZD1480 | CTRPv2 | pan-cancer | AAC | 0.071 | 0.2 |
| mRNA | AZD-2281 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |